Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Robatumumab combinations in advanced solid tumors
NCT00954512Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2009
- Primary completion
- Jun 2011
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of robatumumab in colorectal adenocarcinoma, non-small cell lung cancer (NSCLC), gastric adenocarcinoma, breast cancer, renal cell carcinoma (RCC), sponsored by Merck & Co.. Started Sep 2009; status: terminated.
02
Drugs
robatumumab
03
Conditions
colorectal adenocarcinomanon-small cell lung cancer (NSCLC)gastric adenocarcinomabreast cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00954512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00954512.